The tat-derived cell-penetrating peptide

Cell-Penetrating Peptides: Processes and Applications

Volumn , Issue , 2002, Pages 1-21

  Vivès, Eric ^a   Lebleu, Bernard ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057375972     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (65)

1. Lebleu, B., Delivering information-rich drugs prospects and challenges, Trends Biotechnol., 14, 109-110, 1996.
2. Gordon, J. and Minks, M.A., The interferon renaissance: molecular aspects of induction and action, Microbiol. Rev., 45, 244-266, 1981.
3. Silhol, M., Huez, G., and Lebleu, B., An antiviral state induced in HeLa cells by microinjected poly(rI).poly(rC), J. Gen. Virol., 67, 1867-1873, 1986.
4. Shen, W.C. and Ryser, H.J., Conjugation of poly-L-lysine to albumin and horseradish peroxidase: a novel method of enhancing the cellular uptake of proteins, Proc. Natl. Acad. Sci. USA, 75, 1872-1876, 1978.
5. Shen, W.C. and Ryser, H.J., Poly (L-lysine) and poly (D-lysine) conjugates of methotrexate:different inhibitory effect on drug resistant cells, Mol. Pharmacol., 16, 614-622, 1979.
6. Bayard, B., Bisbal, C., and Lebleu, B., Activation of ribonuclease L by (2′-5′)(A)4-poly(L-lysine) conjugates in intact cells, Biochemistry, 25, 3730-3736, 1986.
7. Lemaitre, M., Bayard, B., and Lebleu, B., Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site, Proc. Natl. Acad. Sci. USA, 84, 648-652, 1987.
8. Wagner, E. et al., Transferrin-polycation conjugates as carriers for DNA uptake into cells, Proc. Natl. Acad. Sci. USA, 87, 3410-3414, 1990.
9. Curiel, D.T., High-efficiency gene transfer mediated by adenovirus-polylysine-DNA complexes, Ann. NY Acad. Sci., 716, 36-56, 1994.
10. Dayton, A.I. et al., The trans-activator gene of the human T cell lymphotropic virus type III is required for replication, Cell, 44, 941-947, 1986.
11. Jeang, K.T., Xiao, H., and Rich, E.A., Multifaceted activities of the HIV-1 transactivator of transcription, Tat, J. Biol. Chem., 274, 28837-28840, 1999.
12. Frankel, A.D. and Pabo, C.O., Cellular uptake of the Tat protein from human immunodeficiency virus, Cell, 55, 1189-1193, 1988.
13. Green, M. and Loewenstein, P.M., Autonomous functional domains of chemically synthesized human immunodeficiency virus Tat trans-activator protein, Cell, 55, 1179-1188, 1988.
14. Fawell, S. et al., Tat-mediated delivery of heterologous proteins into cells, Proc. Natl. Acad. Sci. USA, 91, 664-668, 1994.
15. Anderson, D.C. et al., Tumor cell retention of antibody Fab fragments is enhanced by an attached HIV Tat protein-derived peptide, Biochem. Biophys. Res. Commun., 194, 876-884, 1993.
16. Chen, L.L. et al., Increased cellular uptake of the human immunodeficiency virus-1 Tat protein after modification with biotin, Anal. Biochem., 227, 168-175, 1995.
17. Derossi, D. et al., Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent, J. Biol. Chem., 271, 18188-18193, 1996.
18. Derossi, D. et al., The third helix of the Antennapedia homeodomain translocates through biological membranes, J. Biol. Chem., 269, 10444-10450, 1994.
19. Sabatier, J.-M. et al., Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1, J. Virol., 65, 961-967, 1991.
20. Perez, A. et al., Evaluation of HIV-1 Tat induced neurotoxicity in rat cortical cell culture, J. Neurovirol., 7, 1-10, 2001.
21. Loret, E.P. et al., Activating region of HIV-1 Tat protein: vacuum UV circular dichroism and energy minimization, Biochemistry, 30, 6013-6023, 1991.
22. Ruben, S. et al., Structural and functional characterization of human immunodeficiency virus tat protein, J. Virol., 63, 1-8, 1989.
23. Vivès, E., Brodin, P., and Lebleu, B., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus, J. Biol. Chem., 272, 16010-16017, 1997.
24. Vivès, E. and Lebleu, B., Selective coupling of a highly basic peptide to an oligonucleotide, Tetrahedron Lett., 38, 1183-1186, 1997.
25. Feener, E.P., Shen, W.C., and Ryser, H.J., Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes, J. Biol. Chem., 265, 18780-18785, 1990.
26. Leonetti, J.P. et al., Intracellular distribution of microinjected antisense oligonucleotides, Proc. Natl. Acad. Sci. USA, 88, 2702-2706, 1991.
27. Hughes, J. et al., In vitro transport and delivery of antisense oligonucleotides, Methods Enzymol., 313, 342-358, 2000.
28. Astriab-Fisher, A. et al., Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates, Biochem. Pharmacol., 60, 83-90, 2000.
29. Alahari, S.K. et al., Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothioate and 5' cholesterol-conjugated phosphorothioate antisense oligonucleotides, Mol. Pharmacol., 50, 808-819, 1996.
30. Pooga, M. et al., Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo, Nat. Biotechnol., 16, 857-861, 1998.
31. Wei, Z. et al., Hybridization properties of oligodeoxynucleotide pairs bridged by polyarginine peptides, Nucleic Acids Res., 24, 655-661, 1996.
32. Dunican, D.J. and Doherty, P., Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways, Biopolymers, 60, 45-60, 2001.
33. Vivès, E. et al., Structure activity relationship study of the plasma membrane translocating potential of a short peptide from HIV-1 Tat protein, Lett. Peptide Sci., 4, 429-436, 1997.
34. Lane, D., Awakening angels, Nature, 394, 616-617, 1998.
35. Lu, J. et al., TAP-independent presentation of CTL epitopes by Trojan antigens, J. Immunol., 166, 7063-7071, 2001.
36. Schwarze, S.R. et al., In vivo protein transduction: delivery of a biologically active protein into the mouse, Science, 285, 1569-1572, 1999.
37. Ford, K.G. et al., Protein transduction: an alternative to genetic intervention? Gene Ther., 8, 1-4, 2001.
38. Curiel, D.T. et al., Adenovirus enhancement of transferrin-polylysine-mediated gene delivery, Proc. Natl. Acad. Sci. USA, 88, 8850-8854, 1991.
39. Eguchi, A. et al., Protein transduction domain of HIV-1 Tat protein promotes efficient delivery of DNA into mammalian cells, J. Biol. Chem., 276, 26204-26210, 2001.
40. Weissleder, R. et al., In vivo magnetic resonance imaging of transgene expression, Nat. Med., 6, 351-355, 2000.
41. Lewin, M. et al., Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells, Nat. Biotechnol., 18, 410-414, 2000.
42. Torchilin, V.P. et al., TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors, Proc. Natl. Acad. Sci. USA, 98, 8786-8791, 2001.
43. Mann, D.A. and Frankel, A.D., Endocytosis and targeting of exogenous HIV-1 Tat protein, Embo. J., 10, 1733-1739, 1991.
44. Tyagi, M. et al., Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans, J. Biol. Chem., 276, 3254-3261, 2001.
45. Liu, Y. et al., Uptake of HIV-1 Tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands, Nat. Med., 6, 1380-1387, 2000.
46. Barillari, G.R. et al., The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence, Proc. Natl. Acad. Sci U.S.A., 90, 7941-7945, 1993.
47. Wender, P.A. et al., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters, Proc. Natl. Acad. Sci. USA, 97, 13003-13008, 2000.
48. Polyakov, V. et al., Novel Tat-peptide chelates for direct transduction of technetium-99m and rhenium into human cells for imaging and radiotherapy, Bioconjug. Chem., 11, 762-771, 2000.
49. Drin, G. et al., Physico-chemical requirements for cellular uptake of pAntp peptide. Role of lipid-binding affinity, Eur. J. Biochem., 268, 1304-1314, 2001.
50. Pooga, M. et al., Cell penetration by transportan, FASEB J., 12, 67-77, 1998.
51. Futaki, S. et al., Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery, J. Biol. Chem., 276, 5836-5840, 2001.
52. Mitchell, D.J. et al., Polyarginine enters cells more efficiently than other polycationic homopolymers, J. Pept. Res., 56, 318-325, 2000.
53. Abu-Amer, Y. et al., TAT fusion proteins containing tyrosine 42-deleted IkappaBalpha arrest osteoclastogenesis, J. Biol. Chem., 276, 30499-30503, 2001.
54. Rothbard, J.B. et al., Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation, Nat. Med., 6, 1253-1257, 2000.
55. Kurzchalia, T.V. and Parton, R.G., Membrane microdomains and caveolae, Curr. Opin. Cell. Biol., 11, 424-431, 1999.
56. Gumbleton, M., Abulrob, A.G., and Campbell, L., Caveolae: an alternative membrane transport compartment, Pharm. Res., 17, 1035-1048, 2000.
57. Anderson, R.G. et al., Potocytosis: sequestration and transport of small molecules by caveolae, Science, 255, 410-411, 1992.
58. Dostmann, W.R. et al., Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Ialpha inhibit NO-induced cerebral dilation, Proc. Natl. Acad. Sci. USA, 97, 14772-14777, 2000.
59. Bonny, C. et al., Cell-permeable peptide inhibitors of JNK: novel blockers of betacell death, Diabetes, 50, 77-82, 2001.
60. Li, H. et al., Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide, Proc. Natl. Acad. Sci. USA, 98, 1267-1272, 2001.
61. Stein, S. et al., A disulfide conjugate between anti-tetanus antibodies and HIV (37-72) Tat neutralizes tetanus toxin inside chromaffin cells, FEBS Lett., 458, 383-386, 1999.
62. Caron, N.J. et al., Intracellular delivery of a Tat-eGFP fusion protein into muscle cells, Mol. Ther., 3, 310-318, 2001.
63. Prochiantz, A., Getting hydrophilic compounds into cells: lessons from homeopeptides, Curr. Opin. Neurobiol., 6, 629-634, 1996.
64. Falnes, P.O., Wesche, J., and Olsnes, S., Ability of the Tat basic domain and VP22 to mediate cell binding, but not membrane translocation of the diphtheria toxin A-fragment, Biochemistry, 40, 4349-4358, 2001.
65. Taylor, C.T. et al., Phosphorylation-dependent targeting of cAMP response element binding protein to the ubiquitin/proteasome pathway in hypoxia, Proc. Natl. Acad. Sci. USA, 97, 12091-12096, 2000.